This HTML5 document contains 80 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/chemspider/
n24http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/mesh/concept/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/chebi/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/wikipedia/
n23http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/pharmgkb/
admshttp://www.w3.org/ns/adms#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/bindingdb/
n5http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/pubchem-compound/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n27http://linked.opendata.cz/resource/drugbank/medicinal-product/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/kegg-drug/
owlhttp://www.w3.org/2002/07/owl#
n28http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n22http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/drugbank/
n26http://www.drugs.com/cdi/
n21http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/iuphar/
n30http://www.rxlist.com/cgi/generic2/
n9http://linked.opendata.cz/resource/drugbank/property/
n20http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/guide-to-pharmacology/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB01185/identifier/national-drug-code-directory/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01185
rdf:type
n3:Drug
n3:description
An anabolic steroid that has been used in the treatment of male hypogonadism, delayed puberty in males, and in the treatment of breast neoplasms in women. [PubChem]
n3:dosage
n15:271B50B6-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A: An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology. 2007 Jan;148(1):363-73. Epub 2006 Oct 5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17023534
n3:group
approved illicit
n3:halfLife
9.2 hours
n3:indication
In males, used as replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. In females, for palliation of androgenresponsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal.
owl:sameAs
n11:DB01185 n23:DB01185
dcterms:title
Fluoxymesterone
adms:identifier
n5:6446 n6:D00327 n7:0009-0014-01 n8:46508867 n12:Fluoxymesterone n16:PA164744518 n17:5120 n18:6205 n19:18189 n20:2861 n21:2861 n22:DB01185
n3:mechanismOfAction
Fluoxymesterone is a synthetic androgenic anabolic steroid and is approximately 5 times as potent as natural methyltestosterone. Like testosterone and other androgenic hormones, fluoxymesterone binds to the androgen receptor. It produces retention of nitrogen, sodium, potassium, and phosphorus; increases protein anabolism; decreases amino acid catabolism and decreased urinary excretion of calcium. The antitumour activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.
n3:packager
n24:271B50B3-363D-11E5-9242-09173F13E4C5 n24:271B50B1-363D-11E5-9242-09173F13E4C5 n24:271B50B2-363D-11E5-9242-09173F13E4C5 n24:271B50AF-363D-11E5-9242-09173F13E4C5 n24:271B50B0-363D-11E5-9242-09173F13E4C5
n3:synonym
17α-Methyl-9α-fluoro-11β-hydroxytesterone Fluoximesterona 17alpha-Methyl-9alpha-fluoro-11beta-hydroxytesterone 9-Fluoro-11beta,17beta-dihydroxy-17-methylandrost-4-en-3-one 11beta,17beta-Dihydroxy-9alpha-fluoro-17alpha-methyl-4-androster-3-one 9alpha-Fluoro-11beta-hydroxy-17-methyltestosterone Testosterone, 9-fluoro-11beta-hydroxy-17-methyl- Fluoxymesteronum
n3:toxicity
Side effects include virilization (masculine traits in women), acne, fluid retention, and hypercalcemia.
n3:foodInteraction
Take with food.
n3:proteinBinding
Very high (99%) with 80% to sex hormone binding globulin, 19% to albumin.
n3:synthesisReference
U.S. Patent 2,793,218 U.S. Patent 2,813,881
n28:hasConcept
n29:M0008638
foaf:page
n26:fluoxymesterone.html n30:fluoxy.htm
n3:IUPAC-Name
n9:271B50BB-363D-11E5-9242-09173F13E4C5
n3:InChI
n9:271B50C1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n9:271B50C0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n9:271B50BD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n9:271B50BE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n9:271B50BF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n9:271B50B9-363D-11E5-9242-09173F13E4C5 n9:271B50D1-363D-11E5-9242-09173F13E4C5
n3:logP
n9:271B50BA-363D-11E5-9242-09173F13E4C5 n9:271B50D3-363D-11E5-9242-09173F13E4C5 n9:271B50B7-363D-11E5-9242-09173F13E4C5
n3:logS
n9:271B50B8-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:G03BA01
n3:H-Bond-Acceptor-Count
n9:271B50C7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n9:271B50C8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n9:271B50C2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n9:271B50C3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n9:271B50C5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n9:271B50C4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n9:271B50C6-363D-11E5-9242-09173F13E4C5
n3:absorption
Oral absorption is less than 44%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
76-43-7
n3:category
n3:containedIn
n27:271B50B5-363D-11E5-9242-09173F13E4C5 n27:271B50B4-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n9:271B50CD-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n9:271B50CF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n9:271B50D0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n9:271B50D2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n9:271B50CC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n9:271B50CB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n9:271B50CE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n9:271B50BC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n9:271B50C9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n9:271B50CA-363D-11E5-9242-09173F13E4C5